ResApp (ASX:RAP) share price adds 4% on COVID-19 study rebate

The company's shares are continuing on yesterday's gains…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResApp Health Ltd (ASX: RAP) share price is on the move again today following yesterday's meteoric rise. The digital health company provided another positive release to the ASX today.

At the time of writing, ResApp shares are fetching for 9.3 cents apiece, up 4.49%. It's worth noting that during early morning trade, its shares reached an intraday high of 10.2 cents.

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

ResApp secures rebate on COVID-19 study

Investors are pushing ResApp shares higher after the company secured a cashback for its COVID-19 research program.

According to the release, ResApp advised it has received approval from AusIndustry for its application for an Advanced and Overseas Finding. In particular, this is in relation to the expenditure associated with its COVID-19 clinical studies.

The finding covers the financial years between 2021 to 2023, meaning that ResApp will be eligible for a cash rebate. This refers to the company's COVID-19 overseas research and development expenditure, thus receiving a 43.5% cashback from the Australian government.

As such, ResApp estimates that it will collect a rebate of around $820,000 for the financial year that ended 30 June 2021.

In the United States, the company is currently recruiting participants for its upcoming pilot study. The aim is to collect data to train an algorithm in identifying COVID-19 through cough sounds recorded on a smartphone.

The same participants will also be used in a second study to collect further cough sounds and data on disease progression. ResApp hopes to develop algorithms to remotely monitor patients with COVID-19.

ResApp CEO and managing director, Dr Tony Keating commented:

Our COVID-19 research program is looking at developing algorithms for screening for COVID-19 as well as helping healthcare systems better manage patients with COVID-19, including those with long COVID. This finding, recognising the need to collect COVID-19 cough samples internationally, provides us with a high degree of certainty in planning our programs.

We are very grateful to the Federal Government for their commitment to supporting research and development by Australian companies.

ResApp share price summary

Until recently, ResApp shares were trading at multi-year lows, before shooting up in September. The past month alone has netted investors a return of more than 115%, however year-to-date, is up marginally at 14%.

ResApp commands a market capitalisation of about $83.3 million and has 859 million shares on its books.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A man sits in deep thought with a pen held to his lips as he ponders his computer screen with a laptop open next to him on his desk in a home office environment.
Broker Notes

Buy, hold, sell: BHP, CBA, and Pro Medicus shares

Are analysts bullish on the big names? Let's find out.

Read more »

A man in a business suit scratches his head looking at a graph that started high then dips, then starts to go up again like a rollercoaster.
Broker Notes

Down 38% in March, should you buy the dip on Northern Star shares?

A leading analyst provides his outlook for Northern Stars beaten down shares.

Read more »

A young investor working on his ASX shares portfolio on his laptop.
Share Market News

Challenger shares in focus as APRA unveils new capital rules

APRA finalises new capital rules for longevity product providers, with updates coming at Challenger’s May 2026 Investor Day.

Read more »

A man wearing a red jacket and mountain hiking clothes stands at the top of a mountain peak and looks out over countless mountain ranges.
Opinions

2 incredible ASX shares to buy in April

I rate these potential investments as exciting buys…

Read more »

Two people lazing in deck chairs on a beautiful sandy beach throw their hands up in the air.
Retirement

Why Soul Patts shares are a retiree's dream

This could be one of the best picks for retirees. Here’s why.

Read more »

Different Australian dollar notes in the palm of two hands, symbolising dividends.
Dividend Investing

An ASX dividend stalwart every Australian should consider buying

This business has a great track dividend record. I think it’s a strong buy…

Read more »

Happy shareholders clap and smile as they listen to a company earnings report.
Share Market News

Magellan Financial Group shares in focus after $20m share plan hits target

Magellan Financial Group raised $20 million through its oversubscribed share purchase plan, with new shares set to begin trading in…

Read more »

An excited man stretches his arms out above his head as he reaches a mountain peak.
Share Market News

West African Resources: 2026 production guidance forecasts record gold output

West African Resources guides for record 2026 gold production and considers dividends or buybacks as free cash flow rises.

Read more »